New drug combo aims to wipe out Triple-Negative breast cancer before surgery
NCT ID NCT04230109
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This phase 2 study is testing a drug called sacituzumab govitecan, alone or with pembrolizumab, given before surgery to people with localized triple-negative breast cancer. The goal is to see if these drugs can eliminate all cancer cells in the breast and lymph nodes before surgery. The trial is recruiting 260 participants and will also track long-term outcomes like survival and the need for breast-conserving surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab govitecan (a drug that targets cancer cells) and pembrolizumab (an immunotherapy drug)
- What this could lead to
- If successful, this could lead to a new treatment option before surgery for triple-negative breast cancer, potentially improving the chance of eliminating all cancer cells.
- What could go wrong
- This is a phase 2 trial, so it is still early. The drug combination may not work better than current treatments, and side effects like nausea, fatigue, or immune-related reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ER-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
ACTIVE_NOT_RECRUITINGBoston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-••••
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital - North Shore Cancer Center
RECRUITINGDanvers, Massachusetts, 01923, United States
Contact Phone: •••-•••-••••
Contact
-
Massachusetts General Hospital at Newton-Wellesley Hospital
RECRUITINGNewton, Massachusetts, 02462, United States
Contact Phone: •••-•••-••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Less radiation for breast cancer? a trial tests a smarter, response-based approach
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo tame Triple-Negative breast cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- New drug targets Hard-to-Treat breast cancer in advanced stage